US FDA uncovers fresh faults at India's second-biggest drugmaker Aurobindo Pharma

Auditors uncovered “deficient” manufacturing equipment cleaning and storage controls during a visit last month to an Aurobindo Pharma Ltd. facility in Anakapalli, eastern India, according to a FDA report obtained by Bloomberg News through a Freedom of Information Act request.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/DPbQhwV
via IFTTT